VERICEL CORP (VCEL) Stock Fundamental Analysis
NASDAQ:VCEL - Nasdaq - US92346J1088 - Common Stock - Currency: USD
Taking everything into account, VCEL scores 5 out of 10 in our fundamental rating. VCEL was compared to 556 industry peers in the Biotechnology industry. Both the profitability and the financial health of VCEL get a neutral evaluation. Nothing too spectacular is happening here. VCEL is valued quite expensively, but it does show have an excellent growth rating. With these ratings, VCEL could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year VCEL was profitable.
VCEL had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: VCEL reported negative net income in multiple years.
In the past 5 years VCEL always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 0.70%, VCEL belongs to the best of the industry, outperforming 90.29% of the companies in the same industry.
VCEL has a Return On Equity of 1.01%. This is amongst the best in the industry. VCEL outperforms 91.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.7% | ||
| ROE | 1.01% | ||
| ROIC | N/A |
ROA(3y)-1.54%
ROA(5y)-1.26%
ROE(3y)-2.18%
ROE(5y)-1.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VCEL has a better Profit Margin (1.25%) than 90.83% of its industry peers.
Looking at the Gross Margin, with a value of 72.54%, VCEL belongs to the top of the industry, outperforming 83.09% of the companies in the same industry.
VCEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 1.25% | ||
| GM | 72.54% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y1.27%
2. Health
2.1 Basic Checks
VCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VCEL has been increased compared to 1 year ago.
VCEL has more shares outstanding than it did 5 years ago.
VCEL has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 7.95 indicates that VCEL is not in any danger for bankruptcy at the moment.
The Altman-Z score of VCEL (7.95) is better than 83.45% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that VCEL is not too dependend on debt financing.
VCEL has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.95 |
ROIC/WACCN/A
WACC9.73%
2.3 Liquidity
A Current Ratio of 5.01 indicates that VCEL has no problem at all paying its short term obligations.
VCEL has a Current ratio (5.01) which is in line with its industry peers.
VCEL has a Quick Ratio of 4.58. This indicates that VCEL is financially healthy and has no problem in meeting its short term obligations.
VCEL has a Quick ratio of 4.58. This is comparable to the rest of the industry: VCEL outperforms 51.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.01 | ||
| Quick Ratio | 4.58 |
3. Growth
3.1 Past
VCEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 400.00%, which is quite impressive.
VCEL shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.71% yearly.
VCEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.81%.
The Revenue has been growing by 15.01% on average over the past years. This is quite good.
EPS 1Y (TTM)400%
EPS 3YN/A
EPS 5Y3.71%
EPS Q2Q%-187.5%
Revenue 1Y (TTM)14.81%
Revenue growth 3Y14.95%
Revenue growth 5Y15.01%
Sales Q2Q%2.57%
3.2 Future
VCEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 72.81% yearly.
Based on estimates for the next years, VCEL will show a very strong growth in Revenue. The Revenue will grow by 24.96% on average per year.
EPS Next Y38.83%
EPS Next 2Y105.64%
EPS Next 3Y96.26%
EPS Next 5Y72.81%
Revenue Next Year20.06%
Revenue Next 2Y22.27%
Revenue Next 3Y23%
Revenue Next 5Y24.96%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VCEL is valuated quite expensively with a Price/Earnings ratio of 1266.00.
Based on the Price/Earnings ratio, VCEL is valued cheaply inside the industry as 90.65% of the companies are valued more expensively.
VCEL's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.53.
Based on the Price/Forward Earnings ratio of 49.90, the valuation of VCEL can be described as expensive.
89.75% of the companies in the same industry are more expensive than VCEL, based on the Price/Forward Earnings ratio.
VCEL's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 36.71.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1266 | ||
| Fwd PE | 49.9 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VCEL indicates a rather cheap valuation: VCEL is cheaper than 90.29% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 408.05 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates VCEL does not grow enough to justify the current Price/Earnings ratio.
VCEL's earnings are expected to grow with 96.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)32.6
PEG (5Y)340.9
EPS Next 2Y105.64%
EPS Next 3Y96.26%
5. Dividend
5.1 Amount
VCEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
37.98
+2.52 (+7.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners107.6%
Inst Owner Change-0.21%
Ins Owners1.04%
Ins Owner Change10.93%
Market Cap1.91B
Analysts87.14
Price Target59.67 (57.11%)
Short Float %9.76%
Short Ratio9.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-31.63%
Min EPS beat(2)-78.61%
Max EPS beat(2)15.34%
EPS beat(4)2
Avg EPS beat(4)-4.91%
Min EPS beat(4)-78.61%
Max EPS beat(4)59.63%
EPS beat(8)6
Avg EPS beat(8)15.42%
EPS beat(12)7
Avg EPS beat(12)22.19%
EPS beat(16)8
Avg EPS beat(16)-5.58%
Revenue beat(2)0
Avg Revenue beat(2)-3.82%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)-3.41%
Revenue beat(4)1
Avg Revenue beat(4)-1.65%
Min Revenue beat(4)-4.23%
Max Revenue beat(4)2.84%
Revenue beat(8)3
Avg Revenue beat(8)0.06%
Revenue beat(12)4
Avg Revenue beat(12)-0.53%
Revenue beat(16)6
Avg Revenue beat(16)-0.84%
PT rev (1m)-1.47%
PT rev (3m)-10.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.85%
EPS NY rev (1m)0%
EPS NY rev (3m)-25.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1266 | ||
| Fwd PE | 49.9 | ||
| P/S | 8.02 | ||
| P/FCF | N/A | ||
| P/OCF | 33.22 | ||
| P/B | 6.47 | ||
| P/tB | 6.61 | ||
| EV/EBITDA | 408.05 |
EPS(TTM)0.03
EY0.08%
EPS(NY)0.76
Fwd EY2%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)1.14
OCFY3.01%
SpS4.74
BVpS5.87
TBVpS5.75
PEG (NY)32.6
PEG (5Y)340.9
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.7% | ||
| ROE | 1.01% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 1.25% | ||
| GM | 72.54% | ||
| FCFM | N/A |
ROA(3y)-1.54%
ROA(5y)-1.26%
ROE(3y)-2.18%
ROE(5y)-1.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y1.27%
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | 942% | ||
| Cap/Sales | 26.9% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1437.95% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.01 | ||
| Quick Ratio | 4.58 | ||
| Altman-Z | 7.95 |
F-Score5
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)649.08%
Cap/Depr(5y)464.88%
Cap/Sales(3y)15.17%
Cap/Sales(5y)10.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)400%
EPS 3YN/A
EPS 5Y3.71%
EPS Q2Q%-187.5%
EPS Next Y38.83%
EPS Next 2Y105.64%
EPS Next 3Y96.26%
EPS Next 5Y72.81%
Revenue 1Y (TTM)14.81%
Revenue growth 3Y14.95%
Revenue growth 5Y15.01%
Sales Q2Q%2.57%
Revenue Next Year20.06%
Revenue Next 2Y22.27%
Revenue Next 3Y23%
Revenue Next 5Y24.96%
EBIT growth 1Y25.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2130.55%
EBIT Next 3Y249.59%
EBIT Next 5Y172.93%
FCF growth 1Y-176.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y160.69%
OCF growth 3Y26.05%
OCF growth 5YN/A